Рекомендации 2016 года по лечению дислипидемий (ESC/EAS): фокус на применение нестатиновой гиполипидемической терапии


Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Доступ платный или только для подписчиков

Аннотация

В статье освещены ключевые аспекты рекомендаций 2016 г. по лечению дислипидемий (ESC/EAS). В частности, освещена тактика инициации гиполипидемической терапии, рекомендуемые целевые уровни липопротеидов низкой плотности в различных клинических группах. Важное место уделено возможностям применения новых нестатиновых средств для коррекции дислипидемий: эзетимибу и ингибиторам PCSK9.

Полный текст

Доступ закрыт

Об авторах

Я. И Ашихмин

Юсуповская больница

Email: ya.ashikhmin@gmail.com
к.м.н., кардиолог, зам. генерального директора по медицине

Д. Ю Щекочихин

ФГБОУ ВО «Первый МГМУ им. И.М. Сеченова» Минздрава России

Список литературы

  1. Catapano A., Graham I., De Backer G., Wiklund O., on behalf of Authors/Task Force Members. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur. Heart J. 2016;37:2999-3058.
  2. Stone N.J., Robinson J.G., Lichtenstein A.H. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Circulation. 2014;129:S1-S45.
  3. Lloyd-Jones D.M., Morris P.B., Ballantyne C.M. 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk. J. Am. Coll. Cardiol. 2016;68(1):92-125.
  4. Cannon C.P., Blazing M.A., Giugliano R.P. Ezetimibe added to statin therapy after acute coronary syndromes. N. Engl. J. Med. 2015;372(25): 2387-97.
  5. Hassan M. OSLER and ODYSSEY LONG TERM: PCSK9 inhibitors on the right track of reducing cardiovascular events. Global cardiology science & practice. 2015;(2):20.
  6. Tsujita K., Sugiyama S., Sumida H., Shimomura H., Yamashita T., Yamanaga K., Impact of dual lipidlowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE-IVUS trial. J. Am. Coll. Cardiol. 2015;66(5):495-507.
  7. Abifadel M., et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 2003;34:154-56.
  8. Dadu R.T., Ballantyne C.M. Lipid lowering with PCSK9 inhibitors. Nat. Rev. Cardiol. 2014;11(10):563-75.
  9. Chan J.C., Piper D.E., Cao Q., Liu D., King C., Wang W. A proprotein convertase subtilisin/ kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc. Nat. Acad. Sci. USA. 2009;106:9820-25.
  10. Roth E. M., Taskinen M. R., Ginsberg H., Kastelein J., Colhoun, H. M., Merlet, L. A 24-week study of alirocumab as monotherapy versus ezetimibe: the first phase 3 data of a proprotein convertase subtilisin/kexin type 9 inhibitor. J. Am. Coll. Cardiol. 2014;63(12_S).
  11. Koren M.J., Lundqvist P., Bolognese M., Neutel J.M., Monsalvo M.L., Yang, J. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J. Am. Col. Cardiol. 2014;63(23):2531-40.
  12. Stroes E., Colquhoun D., Sullivan D., Civeira F., Rosenson R.S., Watts G.F Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebocontrolled phase 3 clinical trial of evolocumab. J. Am. Coll. Cardiol. 2014;63(23):2541-48.
  13. Blom D.J., Hala T., Bolognese M., Lillestol M.J., Toth P.D., Burgess L. A 52-week placebocontrolled trial of evolocumab in hyperlipidemia. N. Engl. J. Med. 2014;370:1809-19.
  14. Robinson G., Nedergaard B. S., Rogers W.J., Fialkow J., Neutel J.M. The LAPLACE-2 trial: a phase 3, double-blind, randomized, placebo and ezetimibe controlled, multicenter study to evaluate safety, tolerability and efficacy of evolocumab (AMG 145) in combination with statin therapy in subjects with primary hypercholesterolemia and mixed dyslipidemia. Presented at ACC Scientific Sessions (2014).
  15. Raal F. The addition of evolocumab (AMG 145) allows the majority of heterozygous familial hypercholesterolemic patients to achieve low-density lipoprotein cholesterol goals - results from the phase 3 randomized, double-blind, placebo-controlled study [abstract 400-005]. Presented at ACC Scientific Sessions (2014).
  16. The Lipid Research Clinics Coronary Primary Prevention Trial. Results of 6 years of post-trial follow-up. The Lipid Research Clinics Investigators. Arch. Intern. Med. 1992;152:1399-410.
  17. Landray M.J., Haynes R., Hopewell J.C., Parish S., Aung T., Tomson J., Wallendszus K., Craig M., Jiang L., Collins R., Armitage J. Effects of extended-release niacin with laropiprant in highrisk patients. N. Engl. J. Med. 2014;371:203-12.
  18. Zhao X.Q., Krasuski R.A., Baer J. Effects of combination lipid therapy on coronary stenosis progression and clinical cardiovascular events in coronary disease patients with metabolic syndrome: a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), the HDL- Atherosclerosis Treatment Study (HATS), and the Armed Forces Regression Study (AFREGS). Am. J. Cardiol. 2009;104:1457-64.
  19. Maghsoodi N., Wierzbicki A. Statin myopathy: over-rated and under-treated? Curr. Opin. Cardiol. 2016;31:417-25.
  20. Law M., Rudnicka A.R. Statin safety: a systematic review. Am. J. Cardiol. 2006;97(8A):52C-60C.
  21. Stroes E.S., Thompson P.D., Corsini A., Vladutiu G.D., Raal F.J., Ray К.К. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur. Heart. J. 2015;36:1012-22.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ООО «Бионика Медиа», 2017